title: Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.
abstract: OBJECTIVE
  A North American phase III trial has recently shown that postoperative chemoradiotherapy using the FUFOL Mayo Clinic regimen improves overall survival and relapse-free survival after surgical resection of gastric cancer. However, severe grade 3-4, hematologic and gastrointestinal toxicities were frequent. The aim of this retrospective and multicentric study was to determine the tolerance of a postoperative chemoradiotherapy regimen using LV5FU2 instead of the Mayo Clinic regimen.
  
  
  METHODS
  Twenty-three patients with resected adenocarcinoma of the stomach or gastroesophageal junction at high risk of recurrence were treated with LV5FU2 chemotherapy and radiotherapy (45 Gy in 25 fractions and 5 weeks) delivered to the tumor bed and regional nodes. Nineteen patients were treated with two to four cycles before radiotherapy, then three cycles during radiotherapy, and finally four cycles after radiotherapy; four patients were only given three cycles during radiotherapy.
  
  
  RESULTS
  Of the 23 patients assigned to this protocol, 20 completed treatment (87%). There was only one interruption of treatment because of hematologic or gastrointestinal toxicity. Tolerance of LV5FU2 regimen associated with radiotherapy was excellent: one grade 3 or 4 gastrointestinal toxicity (4.3%), no toxic death, and only one grade 3 neutropenia (4.3%) were reported.
  
  
  CONCLUSIONS
  Radiotherapy combined with LV5FU2 appears to be better tolerated than the Mayo Clinic regimen used in the North American study. These results have to be considered when elaborating future postoperative chemoradiotherapy trials for gastric cancer.
authors.affiliation: Service d'Hépatogastroentérologie, Unité d'Oncologie Digestive, CHU Timone, Marseille, France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Dahan
authors.forename: Dan
authors.initials: D
authors.lastname: Atlan
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Pauline
authors.initials: P
authors.lastname: Ries
authors.forename: Pascal
authors.initials: P
authors.lastname: Artru
authors.forename: Karine
authors.initials: K
authors.lastname: Richard
authors.forename: Gérard
authors.initials: G
authors.lastname: Lledo
authors.forename: Tandat
authors.initials: T
authors.lastname: Nguyen
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Seitz
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil